Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel.
Kim A PappJennifer BeeckerCurtis L CooperMark G KirchhofAnton L PozniakJuergen K RockstrohJan P DutzMelinda J GooderhamRobert GniadeckiH Chih-Ho HongCharles W LyndeCatherine MaariYves PoulinRonald B VenderSharon L WalmsleyPublished in: Dermatology and therapy (2022)
Drug-related benefits and risks when treating a patient with systemic psoriasis therapies are similar for non-HIV patients and PLHIV with a suppressed viral load and normalized CD4 counts. Prior to initiating psoriasis treatment in PLHIV, HIV replication should be addressed by an HIV specialist. Exercise additional caution for patients with a suppressed viral load and discordant CD4 responses on antiretroviral therapy.
Keyphrases
- antiretroviral therapy
- hiv infected
- hiv positive
- human immunodeficiency virus
- hiv aids
- hiv infected patients
- hiv testing
- men who have sex with men
- hepatitis c virus
- south africa
- ejection fraction
- end stage renal disease
- palliative care
- newly diagnosed
- atopic dermatitis
- high intensity
- single cell
- physical activity
- peripheral blood
- climate change